Top headlines: RBI panel under fire, AstraZeneca says Covid shot successful

A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, and more top headlines of the day

Coronavirus, vaccine, covid, drugs, clinical trials
BS Web Team
2 min read Last Updated : Nov 23 2020 | 4:45 PM IST
Rajan, Viral Acharya rip apart RBI over bank licences for large corporates

Former Reserve Bank of India (RBI) governor Raghuram Rajan and deputy governor Viral Acharya on Monday sharply criticised the central bank’s internal working group (IWG) recommendation of allowing industrial houses to float banks. Read on...


Covid-19 vaccine highly effective in preventing Covid-19: AstraZeneca

A vaccine developed by AstraZeneca and the University of Oxford prevented 70% of people from developing the coronavirus in late-stage trials, the team reported Monday. Read on...

Reforms to unleash employment-led growth vs jobless expansion earlier: CEA

Chief economic advisor Krishnamurthy Subramanian said on Monday that the government is converting the Covid crisis into an opportunity to have labour-intensive economic growth, which is a shift from jobless growth seen in the past. Read on...


Kerala govt puts on hold controversial Police Act amendment

The CPI(M)-led Left Democratic Government in Kerala on Monday put on hold implementation of the controversial amendment to the state Police Act citing criticism from various quarters. Read on...

Google delays adopting controversial 30% in-app commission

Facing backlash from developers, Google said on Monday that it will postpone enforcing a 30 per cent commission on in-app purchases of digital content from its Play Store from next January to next September. Read on...

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusReserve Bank of IndiaCoronavirus VaccineCoronavirus TestsRaghuram RajanViral AcharyaKerala government

Next Story